Sat, Aug 2, 2014, 6:13 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Gabelli Utilities AAA Message Board

  • pierrules pierrules Mar 12, 2013 9:10 AM Flag

    OT: GALE

    Frost & Sullivan Applauds Galena Biopharma for its Breakthrough Breast Cancer Vaccine, NeuVax(TM)Font size: A | A | A7:45 AM ET 3/12/13 | PR Newswire
    Based on its recent analysis of the breast cancer vaccines market, Frost & Sullivan recognizes Galena Biopharma, Inc. (NASDAQ: GALE) with the 2013 Global Frost & Sullivan Award for New Product Innovation. The company's revolutionary product, NeuVax(TM), has the potential to address a huge unmet medical need for a breast cancer vaccine and provide significant cost-savings to both patients and governments.

    NeuVax (nelipepimut-S or E75), a nonapeptide, derived from the human epidermal growth factor receptor 2 (HER2) oncogene, is co-administered with the immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) in an intradermal injection. It is the first breast cancer vaccine to reach Phase III clinical trials and could very well emerge as an off-the-shelf cancer immunotherapy treatment to prevent recurrence.

    In Phase II studies, NeuVax was shown to prevent or delay breast cancer recurrence in women with early-stage, high-risk (node positive), HER2 low-to-intermediate (immunohistochemical (IHC) 1+/2+ or fluorescent in situ hybridization (FISH)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.35-0.01(-0.19%)Aug 1 6:24 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Icahn Enterprises, L.P.
NasdaqGSFri, Aug 1, 2014 3:59 PM EDT
Marriott International, Inc.
NasdaqGSFri, Aug 1, 2014 4:00 PM EDT